Alexey V. Danilov, MD, PhD, City of Hope, Duarte, CA, shares some insights into immunotherapeutic agents under investigation for the treatment of chronic lymphocytic leukemia (CLL), commenting on their importance for patients who progress after BTK inhibitors. Prof. Danilov first discusses the promise of CAR-T therapy, and then goes on to highlight the potential use of bispecific T-cell engagers (BiTEs) and natural killer (NK) CARs, and ongoing studies evaluating these agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.